Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29 janv. 2024 16h01 HE
|
Tourmaline Bio, Inc.
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25 janv. 2024 07h00 HE
|
Tourmaline Bio, Inc.
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Announces Proposed Public Offering of Common Stock
24 janv. 2024 16h05 HE
|
Tourmaline Bio, Inc.
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
08 janv. 2024 07h00 HE
|
Tourmaline Bio, Inc.
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 ...
Tourmaline Bio added to the NASDAQ Biotechnology Index
15 déc. 2023 16h00 HE
|
Tourmaline Bio, Inc.
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
14 déc. 2023 07h30 HE
|
Tourmaline Bio, Inc.
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio to Present at Upcoming Investor Conferences
01 nov. 2023 08h00 HE
|
Tourmaline Bio, Inc.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
19 oct. 2023 17h37 HE
|
Tourmaline Bio, Inc.
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases ...
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
17 oct. 2023 17h47 HE
|
Talaris Therapeutics, Inc.
Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq:...
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
06 oct. 2023 17h09 HE
|
Talaris Therapeutics, Inc.
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE)...